Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer

被引:430
作者
Kupperman, Erik [1 ]
Lee, Edmund C. [1 ]
Cao, Yueying [1 ]
Bannerman, Bret [1 ]
Fitzgerald, Michael [1 ]
Berger, Allison [1 ]
Yu, Jie [1 ]
Yang, Yu [1 ]
Hales, Paul [1 ]
Bruzzese, Frank [1 ]
Liu, Jane [1 ]
Blank, Jonathan [1 ]
Garcia, Khristofer [1 ]
Tsu, Christopher [1 ]
Dick, Larry [1 ]
Fleming, Paul [1 ]
Yu, Li [1 ]
Manfredi, Mark [1 ]
Rolfe, Mark [1 ]
Bolen, Joe [1 ]
机构
[1] Millennium Pharmaceut Inc, Cambridge, MA 02139 USA
关键词
MANTLE CELL LYMPHOMA; ENDOPLASMIC-RETICULUM STRESS; UNFOLDED PROTEIN RESPONSE; RELAPSED MULTIPLE-MYELOMA; NON-HODGKINS-LYMPHOMA; EXTENDED FOLLOW-UP; PHASE-II; 20S PROTEASOME; IRREVERSIBLE INHIBITOR; ANTICANCER DRUGS;
D O I
10.1158/0008-5472.CAN-09-2766
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The proteasome was validated as an oncology target following the clinical success of VELCADE (bortezomib) for injection for the treatment of multiple myeloma and recurring mantle cell lymphoma. Consequently, several groups are pursuing the development of additional small-molecule proteasome inhibitors for both hematologic and solid tumor indications. Here, we describe MLN9708, a selective, orally bioavailable, secondgeneration proteasome inhibitor that is in phase I clinical development. MLN9708 has a shorter proteasome dissociation half-life and improved pharmacokinetics, pharmacodynamics, and antitumor activity compared with bortezomib. MLN9708 has a larger blood volume distribution at steady state, and analysis of 20S proteasome inhibition and markers of the unfolded protein response confirmed that MLN9708 has greater pharmacodynamic effects in tissues than bortezomib. MLN9708 showed activity in both solid tumor and hematologic preclinical xenograft models, and we found a correlation between greater pharmacodynamic responses and improved antitumor activity. Moreover, antitumor activity was shown via multiple dosing routes, including oral gavage. Taken together, these data support the clinical development of MLN9708 for both hematologic and solid tumor indications. Cancer Res; 70(5); 1970-80. (C)2010 AACR.
引用
收藏
页码:1970 / 1980
页数:11
相关论文
共 53 条
[1]   Potential for proteasome inhibition in the treatment of cancer [J].
Adams, J .
DRUG DISCOVERY TODAY, 2003, 8 (07) :307-315
[2]   Proteasome inhibitors as new anticancer drugs [J].
Adams, J .
CURRENT OPINION IN ONCOLOGY, 2002, 14 (06) :628-634
[3]   Potent and selective inhibitors of the proteasome: Dipeptidyl boronic acids [J].
Adams, J ;
Behnke, M ;
Chen, SW ;
Cruickshank, AA ;
Dick, LR ;
Grenier, L ;
Klunder, JM ;
Ma, YT ;
Plamondon, L ;
Stein, RL .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1998, 8 (04) :333-338
[4]   The development of proteasome inhibitors as anticancer drugs [J].
Adams, J .
CANCER CELL, 2004, 5 (05) :417-421
[5]  
ANG XL, 2004, SCI STKE, pPE31
[6]   Identification of the yeast 20S proteasome catalytic centers and subunit interactions required for active-site formation [J].
Arendt, CS ;
Hochstrasser, M .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (14) :7156-7161
[7]   The proteasome:: Paradigm of a self-compartmentalizing protease [J].
Baumeister, W ;
Walz, J ;
Zühl, F ;
Seemuller, E .
CELL, 1998, 92 (03) :367-380
[8]   A phase II study of bortezomib in mantle cell lymphoma: The National Cancer Institute of Canada Clinical Trials Group trial IND.150 [J].
Belch, A. ;
Kouroukis, C. T. ;
Crump, M. ;
Sehn, L. ;
Gascoyne, R. D. ;
Klasa, R. ;
Powers, J. ;
Wright, J. ;
Eisenhauer, E. A. .
ANNALS OF ONCOLOGY, 2007, 18 (01) :116-121
[9]  
Chauhan D, 2008, BLOOD, V111, P1654, DOI 10.1182/blood-2006-10-050476
[10]   Structure and functions of the 20S and 26S proteasomes [J].
Coux, O ;
Tanaka, K ;
Goldberg, AL .
ANNUAL REVIEW OF BIOCHEMISTRY, 1996, 65 :801-847